188
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors

, , , , , & show all
Pages 766-769 | Received 03 Mar 2017, Accepted 09 Jul 2017, Published online: 09 Aug 2017
 

Compliance with ethical approval process

The Low Dose TKI study has been reviewed and approved by the Ethical and Scientific review board of the Inserm Clinical Research Center 1402, on 23 July 2015. The registration number of the study is ‘M15-33’.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/doi:10.1080/10428194.2017.1357178.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.